ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

About this update from Immunitybio, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/6591ec5b7ebabc49de9c865d26213ec2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cuifTaOddV.StCrySYWeFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6591ec5b7ebabc49de9c865d26213ec2","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, where no treatment was previously authorized for BCG-unresponsive disease","length":309,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"European Commission conditional marketing authorization enables commercial availability across all 27 European Union (EU) member states plus Iceland, Norway, and Liechtenstein, bringing the total number of countries where ANKTIVA is authorized to 33","length":249,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ANKTIVA is now authorized across four regulatory jurisdictions: the United States (FDA, April 2024), United Kingdom (MHRA, July 2025), Kingdom of Saudi Arabia (SFDA, January 2026), and the European Union (EC, February 2026)","length":223,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"More than 150,000 patients are diagnosed annually with NMIBC across Europe; the European Commission’s decision addresses an unmet medical need where the primary alternative for BCG-unresponsive patients has been radical cystectomy","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Global regulatory footprint of 33 countries built in under two years from initial FDA approval","length":94,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1105,"olType":false},{"type":"text","content":"CULVER CITY, Calif., February 18, 2026--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combinat...

More updates from Immunitybio, Inc.